A practical system for harvesting and monitoring hot topics on the web

This poster briefly describes a practical system named FounderWISE for harvesting and monitoring hot topics on the Web. FounderWISE consists of five components: Web crawler, text classifier, topic detector, topic summarizer and topic analyzer. In this poster we present two key components of topic detector and topic analyzer. The system has been successfully deployed in a few Chinese major government departments.

[1]  S. Oparil,et al.  Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists , 2002, Journal of Human Hypertension.

[2]  Shinji Takai,et al.  Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet , 2003, Journal of hypertension.

[3]  Amy M Franks,et al.  Olmesartan Medoxomil: The Seventh Angiotensin Receptor Antagonist , 2003, The Annals of pharmacotherapy.

[4]  E. Lewis,et al.  The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. , 2002, American journal of hypertension.

[5]  T. Sudhop,et al.  Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil , 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[6]  H. Brunner,et al.  The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview , 2002, Journal of Human Hypertension.

[7]  Xiaojun Wan,et al.  Learning information diffusion process on the web , 2007, WWW '07.

[8]  W. Robert Simons,et al.  Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting , 2003, PharmacoEconomics.

[9]  L R Schwocho,et al.  Pharmacokinetics of CS‐866, a New Angiotensin II Receptor Blocker, in Healthy Subjects , 2001, Journal of clinical pharmacology.

[10]  Toshio Sada,et al.  Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[11]  S G Chrysant,et al.  Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension , 2003, Journal of Human Hypertension.

[12]  S. Miyamoto,et al.  Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. , 1996, Journal of medicinal chemistry.

[13]  Yiming Yang,et al.  Topic Detection and Tracking Pilot Study Final Report , 1998 .

[14]  S. Takai,et al.  Anti-atherosclerotic efficacy of olmesartan , 2002, Journal of Human Hypertension.

[15]  W. Kirch,et al.  The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction , 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[16]  S G Chrysant,et al.  Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension , 2001, Journal of clinical hypertension.

[17]  M. Watanabe,et al.  Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. , 2000, Analytical biochemistry.

[18]  K. Stumpe,et al.  Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist , 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[19]  K. Stumpe,et al.  Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs , 2002, Journal of Human Hypertension.

[20]  E. Schiffrin,et al.  Beyond blood pressure: the endothelium and atherosclerosis progression. , 2002, American journal of hypertension.

[21]  J. Izzo,et al.  Antihypertensive Efficacy of Olmesartan Medoxomil, a New Angiotensin II Receptor Antagonist, as Assessed by Ambulatory Blood Pressure Measurements , 2002, Journal of clinical hypertension.